Memphasys Limited (ASX: MEM) has shown it is leading the way in the cryopreservation of sperm in semen samples enabling the preservation of fertility that might otherwise be compromised.
A study completed by the Australian-based reproductive biotech company has revealed that only cells separated using the Felix™ system exhibited significantly lower levels of DNA fragmentation following cryopreservation.
This is the first study globally to compare electrophoretic separation (using FelixTM) with the DGC and Swim-up sperm isolation techniques on cryopreserved human semen.
Storage of semen via cryopreservation is extensively used in Assisted Reproduction Technologies (“ART”) to preserve male fertility.
The analysis focused on sperm separation protocols for isolating cryopreserved human spermatozoa and found sperm is separated from the cryopreservation medium before clinical use to maximise successful conception and minimise the risk of genetic defects.
The most common separation techniques currently used in the assisted reproductive technology industry are density gradient centrifugation (DGC) and Swim-up.
According to the Company’s findings, the FelixTM System (FelixTM) provides the best separation technique for recovering high-quality sperm post cryopreservation1 for use in assisted reproductive technology (ART).
About Memphasys
Memphasys Limited specialises in reproductive biotechnology for high-value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company’s patented bio-separation technology, utilised by the Company’s most advanced product, the Felix™ System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for artificial human reproduction.
